Articles
Utilising a CTMS to Create a Development Edge
As clinical trials become more globalised and complex, there is an increased need for investigators in all regions of the world, as well as for treatment-naïve patients. The industry faces demanding regulatory needs, as well as the complexities of...
Drug Research
InhibOx and COSMIC Discoveries align to deliver full service drug discovery offering
New service supports big pharma’s drive to outsourcing by offering highly sophisticated technologies for drug discovery chemistry with leading computer-aided drug design services. InhibOx Ltd and the COSMIC Discoveries (the independent service arm of the Institute...
Articles
Scientist gets his mind around Alzheimer’s
It’s not known what causes the disease or how to cure it. And the stakes have never been higher. But one European neuroscientist is leading the charge to uncover new treatments for this neurodegenerative disease. The...
Drug Research
Lycera Announces Research Collaboration with Merck
Lycera Corporation, a biopharmaceutical company pioneering innovative approaches to developing novel oral medicines to treat autoimmune diseases, announced that it has entered into an exclusive research collaboration with Merck to discover, develop and commercialize small molecules that target T-helper...
Drug Research
Shire Strengthens Specialty Pharmaceuticals Team with Senior R&D Appointments
Shire plc, the global specialty biopharmaceutical company, today announced the appointment of two senior Research & Development executives to its Specialty Pharmaceuticals business. Lawson Macartney, DVM, PhD, FRCPath, has been appointed Senior Vice President of the Emerging Business Unit...
Articles
Maximising Drug Discovery Research
Interview with: Teodor Aastrup, Chief Executive Officer, Attana AB "Drug discovery scientists should focus on the biological relevance of their candidate molecules as soon as possible in their research, to ensure a high probability of success...
Drug Research
King Pharmaceuticals and Pain Therapeutics Announce Resubmission of New Drug Application for REMOXY
King Pharmaceuticals®, Inc. and Pain Therapeutics®, Inc. announced that King has resubmitted a New Drug Application (NDA) for REMOXY® (oxycodone) to the U.S. Food and Drug Administration (FDA) in response to a Complete Response letter received by Pain Therapeutics...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read